Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline

Abstract

The combination of 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline or a pharmaceutically acceptable salt thereof with a second therapeutic agent, and its use for the treatment of a) psychiatric disorders with prominent cognitive deficits e.g. chronic PTSD (Post traumatic stress disorder); b) non-degenerative disorders with prominent cognitive deficits e.g. MS (multiple Sclerosis), post-chemotherapy, post-CABG (Coronary artery bypass graft), post-stroke; and/or c) paediatric disorders e.g. autism, mental retardation and learning disabilities, in particular for the treatment of schizophrenia.

1 . - 6 . (canceled) 
     
     
         7 . A method of treating a cognitive memory disorder in a patient in need thereof comprising administering to said patient more than 40 mg of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an acetylcholinesterase inhibitor; wherein said cognitive memory disorder is selected from the group consisting of Alzheimer's disease, age related cognitive decline, mild cognitive impairment, dementia associated with mixed Alzheimer's disease, cardiovascular disease, vascular dementia, dementia with Lewy Bodies, and dementia associated with Huntingdon's disease. 
     
     
         8 . The method of  claim 7 , wherein the cognitive memory disorder is Alzheimer's disease. 
     
     
         9 . The method of  claim 7 , wherein the acetylcholinesterase inhibitor is selected from donepezil, galanthamine, rivastigmine, and any combination thereof. 
     
     
         10 . The method of  claim 7 , wherein the dose of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, is administered once a day. 
     
     
         11 . The method of  claim 7 , wherein the dose of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, is administered more than once a day. 
     
     
         12 . A method for the treatment of a cognitive memory disorder in a patient in need thereof comprising administering to said patient a pharmaceutical composition comprising more than 40 mg of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of an acetylcholinesterase inhibitor, and a pharmaceutically acceptable carrier; wherein said cognitive memory disorder is selected from the group consisting of Alzheimer's disease, age related cognitive decline, mild cognitive impairment, dementia associated with mixed Alzheimer's disease, cardiovascular disease, vascular dementia, dementia with Lewy Bodies, and dementia associated with Huntingdon's disease. 
     
     
         13 . The method of  claim 12 , wherein the cognitive memory disorder is Alzheimer's disease. 
     
     
         14 . The method of  claim 12 , wherein the acetylcholinesterase inhibitor is selected from donepezil, galanthamine, rivastigmine, and any combination thereof. 
     
     
         15 . The method of  claim 12 , wherein the dose of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, is administered once a day. 
     
     
         16 . The method of  claim 12 , wherein the dose of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, is administered more than once a day. 
     
     
         17 . A method for improving the cognitive function of a patient suffering from one or more of Alzheimer's disease, age related cognitive decline, mild cognitive impairment, dementia associated with mixed Alzheimer's disease, cardiovascular disease, vascular dementia, dementia with Lewy Bodies, and dementia associated with Huntingdon's disease, comprising administering to said patient more than 40 mg of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, and a therapeutically effective amount of an acetylcholinesterase inhibitor. 
     
     
         18 . The method of  claim 17 , wherein the acetylcholinesterase inhibitor is selected from donepezil, galanthamine, rivastigmine, and any combination thereof. 
     
     
         19 . The method of  claim 17 , wherein the dose of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, is administered once a day. 
     
     
         20 . The method of  claim 17 , wherein the dose of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, is administered more than once a day. 
     
     
         21 . A method for improving the cognitive function of a patient suffering from one or more of Alzheimer's disease, age related cognitive decline, mild cognitive impairment, dementia associated with mixed Alzheimer's disease, cardiovascular disease, vascular dementia, dementia with Lewy Bodies, and dementia associated with Huntingdon's disease, comprising administering to said patient a pharmaceutical composition comprising more than 40 mg of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, a therapeutically effective amount of an acetylcholinesterase inhibitor; and a pharmaceutically acceptable carrier. 
     
     
         22 . The method of  claim 21 , wherein the acetylcholinesterase inhibitor is selected from donepezil, galanthamine, rivastigmine, and any combination thereof. 
     
     
         23 . The method of  claim 21 , wherein the dose of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, is administered once a day. 
     
     
         24 . The method of  claim 21 , wherein the dose of 3-phenylsulfonyl-8-piperazinyl-1-yl-quinoline or a pharmaceutically acceptable salt thereof, is administered more than once a day.